ArticleJournal of angiogenesis research2010
The potential of nanomedicine therapies to treat neovascular disease in the retina.
Article in Journal of angiogenesis research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases.Discover nano · 2025Review
- The impact of early RPE cell junction loss on VEGF, Ang-2, and TIMP secretion in vitro.Molecular vision · 2023Article
- Intravitreal Administration Effect of Adipose-Derived Mesenchymal Stromal Cells Combined with Anti-VEGF Nanocarriers, in a Pharmaceutically Induced Animal Model of Retinal Vein Occlusion.Stem cells international · 2022Article
- Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD).International journal of molecular sciences · 2021Review
- Nano-Biomaterials for Retinal Regeneration.Nanomaterials (Basel, Switzerland) · 2021Review
- Hyaluronan-Conjugated Carbon Quantum Dots for Bioimaging Use.ACS applied materials & interfaces · 2021Article
- Synergic Effect of Novel WSNanomaterials (Basel, Switzerland) · 2020Article
- Inhibition of choroidal neovascularization by systemic delivery of gold nanoparticles.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Noble Metals and Soft Bio-Inspired Nanoparticles in Retinal Diseases Treatment: A Perspective.Cells · 2020Review
- Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles.Nature communications · 2019Article
- The Different Facades of Retinal and Choroidal Endothelial Cells in Response to Hypoxia.International journal of molecular sciences · 2018Review
- A Novel Nanoparticle Mediated Selective Inner Retinal Photocoagulation for Diseases of the Inner Retina.IEEE transactions on nanobioscience · 2017Article
- GLUT1 activity contributes to the impairment of PEDF secretion by the RPE.Molecular vision · 2016Article
- Drug Delivery Nanoparticles: Toxicity Comparison in Retinal Pigment Epithelium and Retinal Vascular Endothelial Cells.Seminars in ophthalmology · 2016Review
- Targeted radiotherapy with gold nanoparticles: current status and future perspectives.Nanomedicine (London, England) · 2014Review
- Article
- Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice.Experimental eye research · 2013Article
- Novel targets against retinal angiogenesis in diabetic retinopathy.Current diabetes reports · 2012Review
- Administration of vitamin K does not counteract the ectopic mineralization of connective tissues in Abcc6 (-/-) mice, a model for pseudoxanthoma elasticum.Cell cycle (Georgetown, Tex.) · 2011Article
- Nanotechnology and nanotoxicology in retinopathy.International journal of molecular sciences · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neovascular disease in the retina is the leading cause of blindness in all age groups. Thus, there is a great need to develop effective therapeutic agents to inhibit and prevent neovascularization in the retina. Over the past decade, anti-VEGF therapeutic agents have entered the clinic for the treatment of neovascular retinal disease, and these agents have been effective for slowing and preventing the progression of neovascularization. However, the therapeutic benefits of anti-VEGF therapy can be diminished by the need for prolonged treatment regimens of repeated intravitreal injections, which can lead to complications such as endophthalmitis, retinal tears, and retinal detachment. Recent advances in nanoparticle-based drug delivery systems offer the opportunity to improve bioactivity and prolong bioavailability of drugs in the retina to reduce the risks associated with treating neovascular disease. This article reviews recent advances in the development of nanoparticle-based drug delivery systems which could be utilized to improve the treatment of neovascular disease in the retina.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.